Novartis data show nearly 80% of RMS patients treated with ofatumumab had no evidence of NEDA-3
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Doctors will study for a Master of Surgery or Master of Medicine degree at Edge Hill University.
The Minister lauded and extended his gratitude to the scientists who developed the vaccine during pandemic.
73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
It´s the first trial to demonstrate the benefits of dual pathway inhibition
Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Subscribe To Our Newsletter & Stay Updated